Document:

Exhibit 10.58

 

Coronado Biosciences Inc.

 

RESTRICTED STOCK ISSUANCE AGREEMENT

 

This RESTRICTED STOCK ISSUANCE AGREEMENT
(the “Agreement”) is made and entered into as of December 19, 2013, by and between Coronado Biosciences Inc., a Delaware
corporation (the “Company”), and Lindsay A. Rosenwald, MD (the “Grantee”).

 

WHEREAS, in connection with Grantee’s
service to the Company, the Company has agreed to issue One Million Nine Hundred Seventy-Nine Thousand Three Hundred Forty-Six
(1,979,346) shares of Common Stock (the “Shares”).

 

NOW, THEREFORE, the parties agree as follows.

 

1.          Issuance
of Stock. The Company hereby agrees to issue to the Grantee the Shares, which for purposes of this Agreement have a fair market
value equal to the closing price of $2.08 per share on December 18, 2013. All of the Shares received by the Grantee from the Company
pursuant to this Agreement are subject to an option by the Company to repurchase such Shares.

 

2.          Repurchase
Option.

 

(a)          The
later of (i) voluntary termination of the Grantee’s employment with the Company, if Grantee is employed by the Company, and
(ii) Grantee’s voluntary resignation from the Board of Directors of the Company, or refusal to stand for re-election, other
than in both instances due to a disagreement with the Company (referred to as “a voluntary resignation”), shall be
a “Triggering Event.”

 

(b)          In
the event that a Triggering Event occurs, the Company shall have an option (the “Repurchase Option”) for a period of
90 days following the Triggering Event to repurchase any of the Shares that are not vested under the vesting schedule set forth
on Exhibit A hereto (“Unvested Shares”) at the price per share designated pursuant to paragraph (c) hereof.
In the event the Company elects to exercise the Repurchase Option, it shall be exercised by the Company by written notice to the
Grantee, which notice shall specify the number of Shares and the time (not later than 30 days from the date of the Company’s
notice) and place for the closing of the repurchase of the Shares, which shall be reasonably convenient to the Grantee. Upon delivery
of such notice and payment of the purchase price in accordance with the terms herewith, the Company shall become the legal and
beneficial owner of the Shares being repurchased and all rights and interests therein or relating thereto, and the Company shall
have the right to retain and transfer to its own name the number of Shares being repurchased by the Company.

 

(c)          The
purchase price for each Unvested Share repurchased pursuant to the Repurchase Option shall be $0.001 per share.

 

    	 

    	 

    

 

(d)          Said
purchase price shall be paid to the Grantee, at the Company’s option, (i) by delivery of a cashier’s check in
the amount of the purchase price, (ii) by cancellation of any amount of the Grantee’s indebtedness to the Company equal
to the purchase price for the shares being repurchased, or (iii) by a combination of (i) and (ii) so that the combined payment
and cancellation of indebtedness equals such purchase price.

 

(e)          Whenever
the Company shall have the right to repurchase Shares hereunder, the Board of Directors may designate and assign to one or more
assignees the right to exercise all or part of the Repurchase Option, provided that such assignees comply with the terms of this
Agreement. In the event an assignee exercises all or part of the Repurchase Option, the purchase price shall be paid to the Grantee
by delivery of a cashier’s check or in such other form acceptable to the Grantee.

 

3.          Release
of Shares From Repurchase Option/Accelerated Vesting. In the event the Repurchase Option is triggered pursuant to a Triggering
Event and the Company (or its assigns) fails to exercise the Repurchase Option or timely complete the repurchase of any of the
Shares, then, upon the expiration of the 90-day option exercise period, or the subsequent 30-day repurchase period, as the case
may be, any and all such Shares not repurchased by the Company shall be immediately released from the Repurchase Option. In the
event of any termination of Grantee’s employment with the Company or service on the Board of Directors of the Company, that
does not constitute a Triggering Event, then all Shares shall be immediately released from the Repurchase Option. Upon the expiration
or release of the Repurchase Option any unvested Shares shall immediately vest.

 

4.          Restriction
on Transfer. Except for a transfer to a “Related Party” (as defined below), none of the Unvested Shares or any
beneficial interest therein shall be transferred, pledged, hypothecated, encumbered or otherwise disposed of in any way. For purposes
of this Agreement, “Related Party” shall mean a spouse, lineal ancestor or descendant, natural or adopted, a spouse
of a lineal ancestor or descendant, or a trust for the sole benefit of such persons or any of them.

 

All transferees of Shares or any interest
therein (including Related Parties) will receive and hold such Shares or interest subject to the provisions of this Agreement,
and shall agree in writing to take such Shares or interest therein subject to all the terms of this Agreement, including restrictions
on further transfer. Any sale or transfer of the Company’s Shares shall be void unless the provisions of this Agreement are
met.

 

5. Voting and Dividend Rights. Grantee,
as beneficial owner of the Shares, shall have full voting and dividend rights with respect to the Shares during and after the vesting
period. Dividends, if any, declared and paid on the Shares during the vesting period shall be accrued by the Company during the
vesting period and paid to Grantee only if and when the related Shares vest and become non-forfeitable as provided in Sections
2 and 3 hereof. Any such accrued dividends shall be paid to Grantee no later than 30 days after the applicable vesting date. If
any Unvested Shares are repurchased pursuant to the Repurchase Option, then, on the date of such repurchase, Grantee shall no longer
have any rights as a stockholder with respect to such repurchased Shares or any interest therein, and Grantee shall not be entitled
to receive any accrued dividends previously declared on such repurchased Shares.

 

    	 

    	 

    

 

6.          Investment
Intent; Legends on Certificates.

 

(a)          Simultaneously
with the execution hereof, the Grantee has executed and delivered to the Company a copy of the Investment Representation Statement
in the form of Exhibit B hereto concerning the Grantee’s investment intent with respect to the Shares.

 

(b)          The
Grantee acknowledges that the certificates evidencing the Shares shall be endorsed with a legend, in addition to any other legends
required by this Agreement or any other agreement to which the Shares are subject, substantially as follows.

 

			THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW
TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS,
OR THE AVAILABILITY OF EXEMPTIONS FROM SUCH REGISTRATION PROVISIONS.	 

 

 

 

 

 

(c)          The
Grantee understands and agrees that neither the Company nor any agent of the Company shall be under any obligation to recognize
and transfer any of the Shares if, in the opinion of counsel for the Company, such transfer would result in violation by the Company
of any federal or state law with respect to the offering, issuance or sale of securities.

 

7.          Adjustment
for Stock Splits and the Like. All references to the number of Shares shall be appropriately adjusted to reflect any stock
split, stock dividend or other change in the Shares that may be made by the Company after the date of this Agreement.

 

8.          Tax
Consequences.

 

(a)          The
Grantee has reviewed with the Grantee’s own tax advisors the federal, state, local and foreign (if applicable) tax consequences
of this investment and the transactions contemplated by this Agreement. The Grantee is relying solely on such advisors and not
on any statements or representations of the Company or any of its agents. The Grantee (and not the Company) shall be responsible
for the Grantee’s own tax liability that may arise as a result of this investment or the transactions contemplated by this
Agreement. The Grantee understands that Section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), taxes
as ordinary income the difference between the amount paid for the Shares and the fair market value of the Shares as of the date
any restrictions on the Shares lapse. The Grantee understands that he may elect to be taxed at the time the Shares are purchased
rather than when and as the Repurchase Option or 16(b) period expires by filing an election under Section 83(b) of the Code with
the I.R.S. within 30 days from the date of purchase.

 

    	 

    	 

    

 

(b)          THE
GRANTEE ACKNOWLEDGES THAT IT IS THE GRANTEE’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION
UNDER SECTION 83(b), EVEN IF THE GRANTEE REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE GRANTEE’S
BEHALF.

 

(c)          If
the Grantee makes any tax election relating to the treatment of the Shares under the Code, at the time of such election the Grantee
shall promptly notify the Company of such election.

 

9.          General
Provisions.

 

(a)          This
Agreement shall be construed and enforced in accordance with and governed by the laws of the State of New York. This Agreement
represents the entire agreement between the parties with respect to the repurchase of the Shares by the Company and may be modified
or amended only in a writing signed by all parties hereto.

 

(b)          In
addition to the legend set forth in paragraph 6 of this Agreement, the certificates representing the Shares shall be endorsed with
the following legend.

 

			THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RESTRICTED STOCK ISSUANCE AGREEMENT
AND TO THE RESTRICTIONS CONTAINED THEREIN, INCLUDING RESTRICTIONS UPON TRANSFER. A COPY OF THE AGREEMENT WILL BE FURNISHED TO ANY
INTERESTED PARTY UPON WRITTEN REQUEST, WITHOUT CHARGE.	 

  

(c)          Any
notice, demand or request required or permitted to be given pursuant to the terms of this Agreement shall be in writing and shall
be deemed given when delivered personally or deposited in the U.S. mail, first class, certified or registered, return receipt requested,
with postage prepaid, and addressed to the parties at the addresses of the parties set forth at the end of this Agreement or such
other address as a party may designate by notifying the other in writing.

 

(d)          The
rights and obligations of the Company and the Grantee hereunder shall be binding upon, inure to the benefit of and be enforceable
against their respective successors and assigns, legal representatives and heirs. In addition, the rights and obligations of the
Company under Section 2 of this Agreement shall be transferable to any one or more persons or entities as set forth therein.

 

    	 

    	 

    

 

(e)          Either
party’s failure to enforce any provision or provisions of this Agreement, except for the exercise by the Company or its assigns
of the Repurchase Option, shall not in any way be construed as a waiver of any such provision or provisions, nor prevent the party
thereafter from enforcing each and every other provision of this Agreement. The rights granted the parties herein are cumulative
and shall not constitute a waiver of any party’s right to assert all other legal remedies available to it under the circumstances.

 

(f)          The
Company and the Grantee agree, upon request, to execute any further documents or instruments necessary or desirable to carry out
the purposes or intent of this Agreement.

 

(g)          THIS
AGREEMENT DOES NOT IN ANY MANNER OBLIGATE THE COMPANY TO CONTINUE THE GRANTEE’S RELATIONSHIP WITH THE COMPANY.

 

(h)          This
Agreement expresses the entire understanding with respect to the subject matter hereof and supersedes and terminates any prior
oral or written agreements with respect to the subject matter hereof.

 

[Signature Page Follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the
parties have duly executed this Restricted Stock Issuance Agreement as of the day and year first set forth above.

 

	 	COMPANY:
	 	 
	 	Coronado Biosciences Inc.
	 	 
	 	By:	/s/ Lucy Lu
	 	 	Lucy Lu, EVP and CFO

 

	 	GRANTEE:
	 	 
	 	Lindsay A. Rosenwald, MD

 

	 	/s/ Lindsay A. Rosenwald	(SEAL)
	 	 	 	 
	 	Address: 	787 7th Avenue, 48th floor	 
	 	 	New York, NY 10019	 

 

    	 

    	 

    

 

EXHIBIT A

 

VESTING SCHEDULE

 

The shares referenced in the attached Agreement
shall be subject to a vesting schedule whereby the shares shall be released from the Repurchase Option as follows. Vesting shall
be conditioned upon the Grantee’s continued employment with, or service on the Board of Directors of, the Company, except
as provided in Section 3 above.

 

The Shares shall vest, if at all, in three equal installments
as follows:

 

		(a)	one-third of the shares will vest when the Company achieves a fully-diluted market capitalization of $147,862,699 (being two
times the market capitalization on the date of grant of the Shares) provided, however, that if the market capitalization threshold
is met prior to December 19, 2016, vesting shall occur on December 19, 2016;

		(b)	one-third of the shares will vest when the Company achieves a fully-diluted market capitalization of $221,794,048 (being three
times the market capitalization on the date of grant of the Shares) provided, however, that if the market capitalization threshold
is met prior to December 19, 2017, vesting shall occur on December 19, 2017; and

		(c)	one-third of the shares will vest when the Company achieves a fully-diluted market capitalization of $295,725,398 (being four
times the market capitalization on the date of grant of the Shares) provided, however, that if the market capitalization threshold
is met prior to December 19, 2018, vesting shall occur on December 19, 2018.

 

To the extent that the application of a specified percentage
results in a fractional number of Shares, the number of Shares then released will be rounded down to the next whole number of Shares.

 

For purposes of this Agreement, “market capitalization”
shall be determined by multiplying the total number of Shares outstanding (including Shares issuable upon conversion, exchange
or exercise of any derivative security, including without limitation, options, warrants, convertible equity or debt or restricted
equity) by the last reported closing price of the Stock on any Exchange or in the over-the-counter market (the “Market Price”).

 

The shares will accelerate and vest 100% and be fully released
from the Repurchase Option immediately prior to any Change of Control. A “Change of Control” means (a) any transaction,
or series of transactions, resulting in the Company’s stockholders prior to such transaction holding less than a majority
of the voting securities of the Company or the resulting entity, (b) a sale, license or lease of all or substantially all of the
Company’s assets, or (c) any change in the composition of the Board of Directors such that a majority of the Board of Directors
as of the date of this Agreement (“Existing Directors”) (including members of the Board of Directors then in place
that were appointed by a majority of the Existing Directors), fails to represent such majority of the Board of Directors.

 

    	 

    	 

    

 

EXHIBIT B

 

INVESTMENT REPRESENTATION STATEMENT

 

	Grantee:	Lindsay A. Rosenwald, MD
	Issuer:	Coronado Biosciences Inc. (the “Company”)
	Security:	Common Stock
	No. of Shares:	1,979,346

 

In connection with the receipt of the above
securities, the Grantee represents to the Company as follows.

 

1.          Grantee
is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company
to reach an informed and knowledgeable decision to acquire the securities. Grantee is acquiring the securities for investment for
Grantee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof
within the meaning of the Securities Act of 1933, as amended (the “Securities Act”).

 

2.          Grantee
understands that the securities have not been registered under the Securities Act in reliance upon a specific exemption therefrom,
which exemption depends upon, among other things, the bona fide nature of Grantee’s investment intent as expressed herein.

 

3.          Grantee
further understands that the securities must be held indefinitely unless subsequently registered under the Securities Act or unless
an exemption from registration is available. Moreover, Grantee understands that the Company is under no obligation to register
the securities. In addition, Grantee understands that the certificate evidencing the securities will be imprinted with a legend
that prohibits the transfer of the securities unless they are registered or such registration is not required in the opinion of
counsel for the Company.

 

	Date:  December 19, 2013	GRANTEE:
	 	 
	 	/s/ Lindsay A. Rosenwald
	 	Lindsay A. Rosenwald, MDExhibit 10.59 

 

 

CONFIDENTIAL SEPARATION AND RELEASE
AGREEMENT

 

This CONFIDENTIAL SEPARATION
AND RELEASE AGREEMENT (the “Agreement”) is hereby made and entered into this 22nd day of December,
2013, by and between CORONADO BIOSCIENCES, INC. (the “Company” or “Coronado”) and HARLAN
F. WEISMAN, MD (“Dr. Weisman”) (the Company and Dr. Weisman, together, the “Parties”).

 

1.   
       Termination. Dr. Weisman’s employment with the Company and service as
a director will terminate effective December 19, 2013 (the “Termination Date”). Dr. Weisman will be paid
his salary through the Termination Date and for any accrued, unused vacation days. Except as set out in this Agreement, or
any agreements or plans incorporated herein by reference, or as provided by the specific terms of a benefit plan or as
required by law, all employee benefits will end on the Termination Date. Except as set forth in this Agreement, Dr. Weisman
hereby acknowledges that he has been paid all compensation due and owing to him through the Termination Date for labor and
services performed for the Company’s benefit. Dr. Weisman also hereby represents that he has returned or will return to
the Company all Company-owned equipment, computers, smart phones, keys or passes, software, files, discs, materials,
programs, documents (including any copies), as well as all backup tapes that are stored offsite. As to the treatment of funds
already paid into the employee stock purchase plan and roll-over of Dr. Weisman’s 401-k plan, each will be handled in
accordance with the Company’s normal, historical practices or as otherwise required by the Employment Agreement between
Dr. Weisman and the Company dated January 7, 2013, and all such amendments thereto (the “Employment
Agreement”). The Company agrees that Dr. Weisman shall be reimbursed for all reasonable business expenses incurred
through the Termination Date. Finally, Dr. Weisman agrees that as of the Termination Date, he no longer holds a position
within the Company and/or its subsidiaries, including any signature authority or power of attorney with respect to the
Company, its subsidiaries and officers and directors.

 

2.   
       Severance Benefits. If Dr. Weisman executes and does not revoke this
Agreement as provided for in Section 21, below, the Company will provide him with the following payments and benefits
collectively referred to in this Agreement as the “Severance Benefits”:

 

    	Page 1 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

a.           Severance
Pay. Pursuant to the Employment Agreement, the Company will pay Dr. Weisman a severance payment equivalent to twelve (12) months
of his regular base salary. For purposes of this Agreement, the payment of Dr. Weisman’s base salary after the Termination
Date is referred to as the “Severance Pay,” and the period during which he is receiving the Severance Pay is
referred to as the “Severance Period.” The Severance Pay will be paid less applicable federal, state and local
payroll taxes, and other withholdings required by law or authorized by Dr. Weisman. Dr. Weisman will receive the Severance Pay
in accordance with the Company’s payroll procedures beginning on the sixtieth (60th) day following the Termination
Date, as provided for in this Section 2(a). Each payment of the Severance Pay shall be treated as a separate payment for purposes
of Section 409A of the Internal Revenue Code (the “Code”) and the guidance issued thereafter. Because the Company
has determined that Dr. Weisman is a “specified employee” within the meaning of Section 409A of the Code, the timing
of installments of the Severance Pay that are not exempt from Section 409A of the Code will be delayed until the earlier to occur
of: (i) the date that is six months and one day after the Termination Date; or (ii) the date of Dr. Weisman’s death (such
applicable date, the “Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment Date, the
Company will pay to Dr. Weisman a lump sum amount equal to the sum of the suspended installments of Severance Pay that Dr. Weisman
would otherwise have received through the Specified Employee Initial Payment Date if payment of the Severance Pay had not been
so delayed and will commence payment of the balance of the Severance Pay on the Company’s regular paydays in accordance with
its payroll practices thereafter. For purposes of clarification, the “Severance Period” as referred to herein shall
include the entire period between the Termination Date and the date on which Dr. Weisman receives the final installment of the
Severance Pay, notwithstanding the delay of separate payments provided for herein.

 

b.           Stock
Options. On August 16, 2012, the Company granted Dr. Weisman an option to purchase 25,000 shares of Common Stock (the “Original
Option”) under its 2007 Stock Incentive Plan, as amended (the “Plan”). As of August 16, 2013, one-third
of the Original Option had vested and was exercisable for 8,333 shares. On January 7, 2013, the Company granted Dr. Weisman an
additional option to purchase 1,686,590 shares of Common Stock (the “Additional Option,” and together with the
Original Option, the “Options”) under its Plan. As of December 19, 2013, none of the Additional Option had vested.
Pursuant to the Employment Agreement, an additional one-third of the Original Option and one-third of the Additional Option shall
be accelerated and become fully exercisable for a total of 570,530 additional shares, on the Effective Date of this Agreement (as
defined in Section 21 below). Notwithstanding anything to the contrary in the Plan, the Employment Agreement, or in Dr. Weisman’s
stock option agreements relating to the Options, the exercise period for all of Dr. Weisman’s vested Options will be extended
until December 19, 2015, two (2) years from the Termination Date, after which time the Options shall terminate. Except as provided
above, Dr. Weisman’s Options continue to be governed by the terms of the Plan and Dr. Weisman’s stock option agreements.

 

c.           Bonus
Payment. Pursuant to the Employment Agreement, the Company will pay Dr. Weisman an Annual Milestone Bonus in the amount of
Three Hundred Thousand Dollars ($300,000.00), less applicable federal, state and local payroll taxes, and other withholdings required
by law or authorized by Dr. Weisman, for calendar year 2013 (the “Annual Milestone Bonus”). The Annual Milestone
Bonus will be paid in a single lump-sum payment no later than March 15, 2014.

 

d.           New
York Residence. For the twelve (12) month period following the month in which the Termination Date occurs, the Company will
pay Dr. Weisman the amount of Three Thousand Four Hundred Fifty Dollars ($3,450.00) per month, less applicable federal, state and
local payroll taxes, and other withholdings required by law or authorized by Dr. Weisman, representing fifty percent (50%) of the
monthly cost to Dr. Weisman of maintaining his New York apartment.

 

    	Page 2 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

e.           Health
Insurance Continuation. As additional consideration for Dr. Weisman’s execution of this Agreement, the Company will reimburse
Dr. Weisman for the cost of his health continuation coverage premium under the Consolidated Omnibus Budget Reconciliation Act and/or
applicable state continuation coverage law (collectively “COBRA”) on a monthly basis at the same rate paid by
the Company for his health insurance premium during the final month of his employment with the Company for the lesser of: (i) the
twelve (12) month period following the month in which the Termination Date occurs, or (ii) the maximum period permitted by applicable
law. Dr. Weisman may thereafter have the right to continue his health insurance coverage under COBRA entirely at his own expense
for the remaining part of the legally-required continuation period, if any. The Company’s obligation to pay a portion of
Dr. Weisman’s health continuation coverage premiums will terminate if he becomes eligible for substantially equivalent health
benefits from another employer during the reimbursement period, regardless of whether he elects such coverage.

 

If Dr. Weisman does not sign this Agreement
and return it to the Company within twenty-one (21) days of the date it was provided to Dr. Weisman, or if Dr. Weisman revokes
this Agreement pursuant to Section 21, Dr. Weisman will not be entitled to receive the Severance Benefits described above. Dr.
Weisman hereby acknowledges and agrees that but for his execution of this Agreement, he would not be entitled to receive the Severance
Benefits as set out herein. 

 

3.    
      Payment in Full. Dr. Weisman agrees and acknowledges that the Severance Benefits
outlined in Section 2 above exceed the payments he would otherwise be entitled to receive and are specific and sufficient
consideration for the releases and covenants contained in this Agreement. Dr. Weisman further represents and affirms that,
except as set forth in this Agreement, he has been paid and/or received all leave (paid or unpaid), compensation, wages,
bonuses, commissions, and/or benefits to which he may be entitled for any and all work performed for the benefit of the
Company, including but not limited to his work as an employee and that no other leave (paid or unpaid), compensation, wages,
bonuses, commissions and/or benefits are due, except as provided for in this Agreement.

 

4.     
     Release of Claims. In consideration for the promises set forth in this Agreement, Dr.
Weisman, for himself and for his spouse, family, heirs, and anyone acting for him, including representatives, attorneys,
executors, administrators, successors, insurers, and assigns, hereby releases, acquits, and forever discharges the Company,
its past, present and future directors, officers, partners, representatives, shareholders, employees, agents, attorneys,
parents, subsidiaries, affiliates, successors, predecessors and assigns, (the “Company Releasees”) or any
of them, from any and all actions, causes of action, grievances, obligations, costs, expenses, damages, punitive damages,
losses, claims, liabilities, suits, debts, demands, agreements, orders, benefits (including attorneys’ fees and costs
actually incurred), or liabilities of whatever character, in law or in equity, known or unknown, suspected or
unsuspected, matured or unmatured, asserted or not asserted, based on any act, omission, event, occurrence, or non-occurrence
from the beginning of time through the Effective Date of this Agreement, including but not limited to any claims or causes of
action arising out of or in any way relating to Dr. Weisman’s employment, the termination of his employment with the
Company, and/or any other occurrence arising before the Effective Date of this Agreement.

 

    	Page 3 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

This waiver and release
includes, but is not limited to, claims that the Company and/or any of the Company Releasees:

 

a.           have
violated or breached any personnel policies, handbooks, contracts of employment, the Employment Agreement, severance pay agreements
or covenants of good faith and fair dealing;

 

b.           have
discriminated against Dr. Weisman on the basis of age, race, color, sex, national origin, ancestry, disability, religion, harassment,
marital status, parental status, handicap, genetic information, source of income, retaliation, veteran status or entitlement to
benefits, in violation of any local, state or federal law, ordinance or regulation, including, but not limited to: Title VII of
the Civil Rights Act of 1964; 42 U.S.C. § 1981; the Civil Rights Act of 1866, 1964, and 1991; the Age Discrimination in Employment
Act as amended by the Older Workers’ Benefit Protection Act; the Americans With Disabilities Act of 1990; the Rehabilitation
Act of 1973; the Worker Adjustment Retraining and Notification Act; the National Labor Relations Act; the Occupational Safety and
Health Act of 1970; the Equal Pay Act of 1963; the Genetic Information Nondiscrimination Act of 2008; the Sarbanes-Oxley Act; the
Pennsylvania Human Relations Act, 43 P.S. §§ 951 et seq.; Pennsylvania’s Whistleblower Law, 43 P.S. §§
1421 et seq.; the New York State Human Rights Law; the New York Civil Rights Law; the New York City Human Rights Law; the New York
Law on Equal Rights; the New York Law on Equal Pay; the New York Nondiscrimination for Legal Actions Law; the New York Retaliatory
Action by Employers Law; the Massachusetts Fair Employment Practices Act, c. 151B of the Massachusetts General Laws; the Massachusetts
Civil Rights Act, M.G.L. c. 12, §§ 11H and 11I; the Massachusetts Equal Rights Act, M.G.L. c. 93, § 102 and M.G.L.
c. 214, § 1C; the Massachusetts Labor and Industries Act, M.G.L. c. 149, § 1 et seq.; the Massachusetts Privacy Act,
M.G.L. c.214, §1B; and/or the Massachusetts Maternity Leave Act, M.G.L. c. 149, §105(d) (all as amended);

 

c.           have
violated public policy or common law, including claims under state and federal law for retaliatory discharge, negligent hiring
or supervision, breach of contract, wrongful termination, tort, personal injury, invasion of privacy, defamation, intentional or
negligent infliction of emotional distress and/or mental anguish, intentional interference with contract, negligence, detrimental
reliance, loss of consortium to Dr. Weisman or to any member of his family, and/or promissory estoppel;

 

d.           have
failed to pay wages or otherwise violated any law governing the payment of wages or protection of workers seeking payment for work
performed, including, but not limited to laws governing the payment of wages in Pennsylvania, Massachusetts and New York state,
including the Pennsylvania Equal Pay Law, P.L. 1913, No. 694, the Pennsylvania Wage Payment and Collection Act, P.L. 637, No. 329,
New York Wage-Hour Law, the New York Wage Payment Law, the New York Wage Theft Prevention Act, the Massachusetts Payment of Wage
Act, M.G.L. c. 149, § 148, and other laws in the Commonwealth governing the payment of wages including but not limited to
Massachusetts’s “Blue Laws,” and any other federal, state or local statutory and/or common laws; and/or

 

    	Page 4 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

e.           have
violated any other federal, state or local law, ordinance or regulation, including, but not limited to the Employee Retirement
Income Security Act of 1974 (ERISA), the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), the Massachusetts Small
Group Continuation of Coverage Law, Pennsylvania’s Act 2 of 2009, N.Y. Ins. Law § 3221(m), and/or the Family and Medical
Leave Act (FMLA).

 

Excluded from this
release are the following rights and claims, referred to collectively as the “Excluded Claims”: (i) any claims
which cannot be waived by law, including but not limited to the right to file a charge with or participate in an investigation
conducted by the Massachusetts Commission Against Discrimination, the U.S. Equal Employment Opportunity Commission or any other
governmental agency charged with investigating complaints, whether based in employment discrimination, violations of laws governing
the payment of wages, or otherwise (collectively, “Governmental Agencies”), provided that Dr. Weisman is waiving,
however, his right to any monetary compensation, or other relief should Governmental Agencies pursue any claims on his behalf;
(ii) if applicable, Dr. Weisman’s right to indemnification by the Company as an officer or director to the fullest extent
permitted by applicable law and/or the Company’s governing documents; (iii) if applicable, Dr. Weisman’s right to coverage
and to make a claim under the director and officer insurance policy of the Company; (iv) any claims related to Dr. Weisman’s
vested benefits under any Company qualified benefit plan(s); and/or (v) claims for a breach of this Agreement.

 

Dr. Weisman expressly
agrees and understands that this release and waiver of claims is a GENERAL RELEASE, and that any reference to specific claims
arising out of or in connection with his employment is not intended to limit the release and waiver of claims. Dr. Weisman, his
heirs, executors, beneficiaries, legal representatives and assigns, and individually and/or in their beneficial capacity, further
agree never to institute against the Company or any of the Company Releasees any lawsuit with respect to any claim or cause of
action of any type which may have existed at any time prior to the date of the execution of this Agreement.

 

5.  
        No Filings/Covenant Not To Sue. Dr. Weisman represents that he has not
filed any action, claim, charge, or complaint against the Company, or any of the Company Releasees, with any agency, court,
governmental entity and/or Governmental Agencies. Dr. Weisman further represents that he has not communicated or otherwise
initiated contact with a governmental body, agency or entity and/or Governmental Agencies for the purpose of discussing, in
any capacity, issues, concerns, behaviors, patterns, practices or actual or perceived violations of any federal, state or
local law, including but not limited to the federal False Claims Act, the Securities and Exchange Commission’s
Dodd-Frank Act Whistleblower Program, the Stark law or any similar type of qui tam statute or program and has no basis
to communicate or otherwise initiate such contact based upon his knowledge of and/or work or service performed for the
Company.

 

    	Page 5 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

Dr. Weisman agrees
as part of the material consideration for the Company’s payment of the Severance Benefits that he will not institute, maintain,
prosecute, induce, or counsel or assist any person or entity in the instigation, commencement, maintenance, presentation, or prosecution
of, any lawsuit, action, complaint, claim, or administrative or legal proceeding against the Company or any of the other Company
Releasees, or in any way voluntarily participate or cooperate in any such actions or proceedings; provided that, nothing in this
Agreement or in this Section 5 prohibits Dr. Weisman from instituting, maintaining or participating in any lawsuit, action or proceeding
with respect to any Excluded Claims.  This prohibition applies to every stage of any action, lawsuit, or proceeding, including,
but not limited to, any pre-litigation investigation or fact gathering, pre-trial or pre-hearing investigation or preparation,
hearing, arbitration proceedings, or trial, and bars Dr. Weisman from voluntarily testifying, providing documents or information,
advising, counseling, or providing any other form of voluntary assistance to any person or entity who wishes to make or who is
making any claim against Company or any of the other Company Releasees.  Nothing in this Section shall prohibit Dr. Weisman
from complying with a properly-served and lawfully issued subpoena or order issued by a court of competent jurisdiction that may
elicit truthful information or documentation regarding Company or any of the Company Releasees.  However, should Dr. Weisman
receive any such subpoena or order, within two (2) business days following his receipt of same, he shall provide a copy of the
subpoena or court order to Company’s Chief Executive Officer, by overnight mail, hand delivery, or facsimile, in order to
provide Company with notice of the subpoena or order, including:  (1) the case name, jurisdiction and index, docket, or other
identification number or designation of the action or proceeding within which the subpoena or order has been issued; (2) the date
upon which compliance with the subpoena or order is due; and (3) the location at which compliance with the subpoena or order
has been requested.  If approached by anyone for counsel or assistance in the presentation, maintenance, or prosecution of
any lawsuit, action, complaint, claim, or administrative or legal proceeding against Company or any of the other Company Releasees,
Dr. Weisman shall state no more than that he cannot provide counsel or assistance.

 

6.    
      Tax Liability and Indemnification. Dr. Weisman acknowledges that he has not
relied on any statements or representations by the Company or its attorneys with respect to the tax treatment of the
Severance Benefits. In the event of an inquiry by any governmental or taxing authority, no Party or Party representative
shall assert any position contrary to the terms of this Agreement.

 

7.      
    Restrictive Covenants. Dr. Weisman acknowledges and agrees that pursuant to the Employment
Agreement, he is and remains bound by certain restrictive covenants set forth in Section 9 of the Employment Agreement (the
“Restrictive Covenants”) during the Severance Period and for the Restricted Period (as defined in the
Employment Agreement). The Restrictive Covenants in Section 9 of the Employment Agreement include an agreement not to compete
against the Company and an agreement not to solicit the Company’s employees and clients. Dr. Weisman acknowledges that
the Restrictive Covenants survive the termination of his employment and the termination of his service pursuant to the
Employment Agreement. The Parties agree that the Restrictive Covenants are incorporated by reference as if fully set forth
herein and a breach of those provisions will also constitute a breach of this present Agreement.

 

    	Page 6 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

8.    
      Post-Employment Cooperation and Notification of Employment. Dr. Weisman agrees to
fully cooperate with the Company in all matters relating to the winding up of his work, including but not limited to, any
current or future litigation in which the Company is or becomes involved. In the event Dr. Weisman’s assistance is
needed after the Severance Period, the Company agrees to compensate Dr. Weisman at an hourly rate of $500 for all time spent
providing such assistance. Dr. Weisman also agrees that he will provide the Company with no fewer than five (5) business
days’ notice of his intent to accept employment or engagement as a consultant or independent contractor by or for a
person or entity other than the Company during the Severance Period in order for the Company to determine, in its reasonable
and good faith discretion, if such new employer is a competitor of the Company and/or if there is a reasonable risk that such
new employment or engagement may violate the provisions of the Restrictive Covenants. This notice of intent to accept
employment will identify the new employer, list Dr. Weisman’s anticipated title and describe his anticipated duties,
and shall be directed to the attention of the Company’s Chief Executive Officer.

 

9.    
      No Admissions/No Representations. Dr. Weisman understands, acknowledges and agrees
that the release set out in Section 4 of this Agreement is a final compromise of any potential claims by Dr. Weisman against
the Company and the Company Releases. Dr. Weisman further understands, acknowledges and agrees that the release set out in
Section 4 of this Agreement in connection with his employment by and service to the Company is not an admission by the
Company or the Company Releases that any such claims exist or that the Company or any of the Company Releases are liable for
any such claims. The Parties each individually and independently acknowledge that, except as expressly set forth herein, no
representation of any kind or character has been made to induce the execution of this Agreement. The Parties individually
warrant for themselves that each is competent to execute this Agreement and accepts full responsibility therefore. The
Parties further agree that this Agreement shall be deemed to have been prepared by the Parties jointly, and no ambiguity
shall be resolved against any Party on the premise that it was responsible for drafting this Agreement, in whole or in
part.

 

10.         Confidentiality.
Dr. Weisman hereby agrees and acknowledges that, except as otherwise expressly provided for herein, his post-employment obligations
to the Company pursuant to the Employment Agreement and the Proprietary Information and Inventions Agreement (the “Confidentiality
Agreements”) signed in connection with his employment with the Company remain in full force and effect,
notwithstanding the termination of his employment and service thereunder. Dr. Weisman agrees to carefully guard the Company’s
confidential and proprietary information that Dr. Weisman learned or had access to during Dr. Weisman’s work for and on behalf
of the Company.

 

11.         Mutual
Non-Disparagement. Dr. Weisman agrees not to publicly or privately criticize, denigrate, or disparage or make any statements
or remarks that have the intended or foreseeable effect of harming the reputation of the Company and/or any of its present and
former directors, officers, partners, representatives, shareholders, employees, agents, attorneys, insurers, parents, subsidiaries,
affiliates, successors, predecessors and assigns through any means of communication, including, but not limited to, print or broadcast
media or any Internet communication outlet. The Company will instruct its officers and directors not to denigrate, defame, or disparage
Dr. Weisman, his services, business and manner of doing business. Upon inquiry from any third party, the Company will only release
Dr. Weisman’s dates of employment and positions held, unless Dr. Weisman provides written authorization and a release for
the Company to provide additional information. Dr. Weisman will be permitted the opportunity to provide input regarding the press
release announcing the termination of his employment.

 

    	Page 7 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

12.         Relief
and Enforcement. Dr. Weisman understands and agrees that any material breach of this Agreement by him will relieve the Company
of its obligation to provide the Severance Benefits as set out in Section 2, above. Dr. Weisman also understands and agrees that
if he violates the terms of Sections 1, 5, 7, 8, 10 or 11 of this Agreement, he will cause injury to the Company (and/or one or
more of the Company Releasees) that will be difficult to quantify or repair, so that the Company (and/or the Company Releasees)
will have no adequate remedy at law. Accordingly, Dr. Weisman agrees that if he violates Sections 1, 5, 7, 8, 10 or 11 of this
Agreement, the Company (or the Company Releasees) will be entitled as a matter of right to obtain an injunction from a court of
law, restraining him from any further violation of this Agreement. The right to an injunction is in addition to and not in lieu
of any other remedies that the Company (or the Company Releasees) has at law or in equity. In any action to enforce the terms of
this Agreement, the prevailing party shall be entitled to recover its reasonable attorneys’ fees. In order to be a “prevailing
party” the Party who institutes any legal action must succeed on substantially all of the claims brought as part of such
action; otherwise, the Party defending such action shall be the prevailing party.

 

13.         No
Re-employment. Dr. Weisman hereby covenants and agrees that he will not knowingly seek or accept employment with the Company
or any of its affiliates, parents, subsidiaries, successors, predecessors and assigns. Dr. Weisman further agrees that the execution
of this Agreement is good and sufficient cause for the Company and its affiliates, parents, subsidiaries, successors, predecessors
and assigns to reject any application by Dr. Weisman for employment.

 

14.         Voluntary
Execution. By signing below, Dr. Weisman acknowledges that he has read the foregoing Agreement, that he understands its contents
and that he has relied upon or had the opportunity to seek the legal advice of his attorney, who is the attorney of his own choosing.

 

15.         Reservation
of Rights/Waiver. Both Parties reserve the right to sue for breach of contract in the event that there is a breach of the covenants
and/or obligations set forth herein. The failure of either Party to insist upon strict adherence to any term of this Agreement
on any occasion shall not be considered a waiver thereof or deprive that Party of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement.

 

16.         Choice
of Law. This Agreement shall be governed by and interpreted under the laws of the Commonwealth of Massachusetts without regard
for any conflict of law principle that would dictate the application of the laws of another jurisdiction.

 

17.         Entire
Agreement/Severability. This Agreement (inclusive of the Confidentiality Agreements) contains the entire, final expression
of the agreement and understanding by and between the Parties with respect to the matters herein referred to, and it is a complete
and exclusive statement of the terms thereof. This Agreement shall supersede all prior understandings, oral and written, hereto
before had between the Parties. No amendments, representations, promises, agreements, or understandings, written or oral, not herein
contained shall be valid or binding unless the same is in writing and signed by both Parties. Should any provision of this Agreement
be declared or be determined by any agency or court to be illegal or invalid, the validity of the remaining parts, terms or provisions
shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not a part of this Agreement.

 

    	Page 8 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

18         Binding Nature
of Agreement. This Agreement shall inure to the benefit of and shall be binding upon Dr. Weisman, his heirs, administrators,
representatives, executors, successors and assigns and upon the successors and assigns of the Company.

 

19.         Headings.
The headings of the sections of this Agreement are for convenience only and are not binding on any interpretation of this Agreement.

 

20.         Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

21.         Review
and Effective Date.

 

a.           Agreement
is Knowing and Voluntary. Dr. Weisman understands, agrees and acknowledges that he:

 

1.          has
carefully read and/or had read to him and fully understands all of the provisions of this Agreement;

 

2.          knowingly
and voluntarily agrees to all of the terms set forth in this Agreement;

 

3.          knowingly
and voluntarily intends to be legally bound by the same; and

 

4.          was
advised, and hereby is advised in writing, to consider the terms of this Agreement and consult with an attorney of Dr. Weisman’s
choice prior to executing this Agreement.

 

b.           21-Day
Consideration Period. Dr. Weisman acknowledges that the Company
has offered him twenty-one (21) days to consider the terms and conditions of this Agreement and to decide whether to sign and enter
into this Agreement. In the event that Dr. Weisman elects to sign this Agreement prior to the expiration of the twenty-one (21)
day period, he acknowledges that in doing so, he will voluntarily waive the balance of the twenty-one (21) days permitted. Dr.
Weisman understands and agrees that any change to the initially drafted terms of this Agreement are not material and will not restart
the running of this twenty-one (21) day period.

 

c.           7-Day
Revocation Period. Dr. Weisman has seven (7) days after his execution of this Agreement to revoke his acceptance of it (the
“Revocation Period”). Any such revocation must be made in writing to be received by Robyn Hunter at the Company’s
Burlington, Massachusetts office by the close of business on the seventh (7th) day following Dr. Weisman’s signature
to be effective. The Parties acknowledge and agree that this Agreement is neither effective nor enforceable and neither Party is
obligated to perform the promises contained herein in the event that the Agreement is revoked or until expiration of the seven
(7) day revocation period, the “Effective Date” of this Agreement.

 

[Remainder of page left intentionally
blank; signature page immediately follows.]

 

    	Page 9 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

    	 

    

 

THE PARTIES EACH ACKNOWLEDGE
FOR THEMSELVES THAT THEY EACH HAVE CAREFULLY READ THE FOREGOING CONFIDENTIAL SEPARATION AND RELEASE AGREEMENT, AND FULLY UNDERSTAND
EACH OF ITS TERMS. THE PARTIES FURTHER ACKNOWLEDGE FOR THEMSELVES THAT EACH HAS FULL KNOWLEDGE AND UNDERSTANDING OF THE AGREEMENT’S
LEGAL CONSEQUENCES AND EACH INTENDS TO BE BOUND BY SAME.

 

	Dated:	20 December 2013	 	/s/ Harlan F. Weisman, MD
	 	 	 	HARLAN F. WEISMAN, MD
	 	 	 	 
	Dated:	12/22/13	 	CORONADO BIOSCIENCES, INC.
	 	 	 	 
	 	 	 	/s/ Lindsay Rosenwald
	 	 	 	By:  Lindsay Rosenwald
	 	 	 	Title:  Chairman/CEO

 

    	Page 10 of 10
Confidential Separation and Release Agreement:
H. Weisman and Coronado Biosciences, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]